Benzofuran-based hybrid compounds for the inhibition of cholinesterase activity, β amyloid aggregation, and Aβ neurotoxicity

Journal of Medicinal Chemistry

Volumn 51, Issue 10, 2008, Pages 2883-2886

  Rizzo, Stefano ^a   Rivière, Céline ^b   Piazzi, Lorna ^a   Bisi, Alessandra ^a   Gobbi, Silvia ^a   Bartolini, Manuela ^a   Andrisano, Vincenza ^a   Morroni, Fabiana ^a   Tarozzi, Andrea ^a   Monti, Jean Pierre ^b   Rampa, Angela ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Bordeaux Segalen University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BENZOFURAN DERIVATIVE; BENZYLAMINE DERIVATIVE; BETA AMYLASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CURCUMIN; N METHYL N BENZYLAMINE; RIVASTIGMINE; SKF 64346;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BRAIN PROTECTION; DRUG DESIGN; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; FIBER; HUMAN; HUMAN CELL; NEUROTOXICITY; PROTEIN AGGREGATION;

ACETYLCHOLINESTERASE; AMYLOID; AMYLOID BETA-PROTEIN; BENZOFURANS; BUTYRYLCHOLINESTERASE; CELL LINE; CELL SURVIVAL; CHOLINESTERASE INHIBITORS; HUMANS; NEURONS; PEPTIDE FRAGMENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 43949112301     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8002747     Document Type: Article

References (30)

1. Terry, A. V.; Buccafusco, J. J. The cholinergic hypothesis of age and Alzheimer's disease related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. 2003, 306, 821-827.
2. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
3. Selkoe, D. J. Normal and abnormal biology of the beta-amyloid precursor protein. Annu. Rev. Neurosci. 1994, 17, 489-517.
4. Talaga, P. β-Amyloid aggregation inhibitors for the treatment of Alzheimer's disease: dream or reality. Mini-Rev. Med. Chem. 2001, 1, 175-186.
5. Estrada, L. D.; Soto, C. Disrupting β-amyloid aggregation for Alzheimer's disease treatment. Curr. Top. Med. Chem. 2007, 7, 115-126.
6. Greig, N. H.; Utsuki, T.; Yu, Q.; Zhu, X.; Holloway, H. W.; Perry, T.; Lee, B.; Ingram, D. K.; Lahiri, D. K. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr. Med. Res. Opin. 2001, 17, 159-165.
7. Giacobini, E. Acetyl- and butyrylcholinesterase inhibition by rivastigmine in cerebrospinal fluid of patiens with Alzheimer's disease correlates with cognitive benefit. J. Neural Transm. 2002, 109, 1053-1065.
8. Darvesh, S.; Hopkins, D. A.; Geula, C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. 2003, 4, 131-138.
9. Giacobini, E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharm. Res. 2004, 50, 433-440.
10. Greig, N. H.; Utsuki, T.; Ingram, D. K.; Wang, Y.; Pepeu, G.; Scali, C.; Yu, Q. S.; Mamczarz, J.; Holloway, H. W.; Giordano, T.; Chen, D.; Furukawa, K.; Sambamurti, K.; Brossi, A.; Lahir, D. K. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17213-17218.
11. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48, 6523-6543.
12. Youdim, M. B. H.; Buccafusco, J. J. Multi-functional drugs for various CNS target in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 2005, 26, 27-35.
13. Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Mancini, F.; Recanatini, M.; Andrisano, V.; Rampa, A. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg. Med. Chem. Lett. 2008, 18, 423-426.
14. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008, 51, 347-372.
15. Rampa, A.; Piazzi, L.; Belluti, F.; Gobbi, S.; Bisi, A.; Bartolini, M.; Andrisano, V.; Cavrini, V.; Cavalli, A.; Recanatini, M.; Valenti, P. Acetylcholinesterase Inhibitors: SAR and kinetic studies on ω-[N- methyl-N-(3-alkylcarbamoyloxyphenyl)-methyl]-aminoalkoxyaryl derivatives. J. Med. Chem. 2001, 44, 3810-3820.
16. Belluti, F.; Rampa, A.; Piazzi, L.; Bisi, A.; Gobbi, S.; Bartolini, M.; Andrisano, V.; Cavalli, A.; Recanatini, M.; Valenti, P. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced β-amyloid aggregation. J. Med. Chem. 2005, 48, 4444-4456.
17. Piazzi, L.; Belluti, F.; Bisi, A.; Gobbi, S.; Rizzo, S.; Bartolini, M.; Andrisano, V.; Recanatini, M.; Rampa, A. Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg. Med. Chem. 2007, 15, 575-585.
18. Howlett, D. R.; Perry, A. E.; Godfrey, F.; Swatton, J. E.; Jennings, K. H.; Spitzfaden, C.; Wadsworth, H.; Wood, S. J.; Markwell, R. E. Inhibition of fibril formation in β-amyloid peptide by a novel series of benzofurans. Biochem. J. 1999, 340, 283-289.
19. Twyman, L. J.; Allsop, D. A short synthesis of the β-amyloid (Aβ) aggregation inhibitor 3-p-toluoyl-2-[4′-(3- diethylaminopropoxy)-phenyl]-benzofuran. Tetrahedron Lett. 1999, 40, 9383-9384.
20. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M. A new rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95.
21. Rivière, C.; Richard, T.; Quentin, L.; Krisa, S.; Mérillon, J.-M.; Monti, J.-P. Inhibitory activity of stilbenes on Alzheimer's β-amyloid fibrils in vitro. Bioorg. Med. Chem. 2007, 15, 1160-1167.
22. Klegeris, A.; Walker, D. G.; McGeer, P. L. Activation of macrophages by Alzheimer beta amyloid peptide. Biochem. Biophys. Res. Commun. 1994, 199, 984-991.
23. Pike, C. J.; Walencewicz-Wasserman, A. J.; Kosmoski, J.; Cribbs, D. H.; Glabe, C. G.; Cotman, C. W. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem. 1995, 64, 253-265.
24. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 2004, 75, 742-750.
25. Tarozzi, A.; Morroni, F.; Hrelia, S.; Angeloni, C.; Marchesi, A.; Cantelli-Forti, G.; Hrelia, P. Neuroprotective effects of anthocyanins and their in vivo metabolites in SH-SY5Y cells. Neurosci. Lett. 2007, 424, 36-40.
26. Shearman, M. S.; Hawtin, S. R.; Tailor, V. J. The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by beta-amyloid peptides. J. Neurochem. 1995, 65, 218-227.
27. Farlow, M.; Anand, R.; Messina, J., Jr.; Hartman, R.; Veach, J. A 52-week study of the efficacy of rivastigmin in patients with mild to moderately severe Alzeimer's disease. Eur. Neurol. 2000, 44, 236-241.
28. Bartolini, M.; Bertucci, C.; Bolognesi, M. L.; Cavalli, A.; Melchiorre, C.; Andrisano, V. Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. ChemBioChem 2007, 8, 2152-2161.
29. Johansson, A. S.; Bergquist, J.; Volbracht, C.; Päiviö, A.; Leist, M.; Lannfelt, L.; Westlind-Danielsson, A. Attenuated amyloid-beta aggregation and neurotoxicity owing to methionine oxidation. NeuroReport 2007, 18, 559-563.
30. Clementi, M. E.; Marini, S.; Coletta, M.; Orsini, F.; Giardina, B.; Misiti, F. Abeta(31-35) and Abeta(25-35) fragments of amyloid beta-protein induce cellular death through apoptotic signals: role of the redox state of methionine-35. FEBS Lett. 2005, 579, 2913-2918.